Abstract
Losartan has been shown to be a substrate of the drug-efflux transporter MDR1, encoded by the ABCB1 gene. ABCB1 c.2677G>T and c.3435C>T variants are known to be associated with reduced expression and function of P-glycoprotein (P-gp). We investigated the effects of ABCB1 diplotype on the pharmacokinetics of losartan. Thirty-eight healthy Korean volunteers with different ABCB1 diplotypes [c.2677G> T and c.3435C>T; carriers of GG/CC (n = 13), GT/CT (n = 12) and TT/TT (n = 13) diplotype] were recruited and administered a single 50 mg oral dose of losartan potassium. Losartan and its active metabolite E-3174 samples in plasma and urine were collected up to 10 and 8 h after drug administration, respectively, and the concentrations of both samples were determined by HPLC method. Significant differences were observed in Cmax of losartan and losartan plus E-3174 (Lo + E) among the three diplotype groups (both P < 0.01). However, the power of the performed test is less than the desired power (0.800). The tmax of losartan and E-3174 in three diplotype groups were also significantly different (both P < 0.01). The AUC values of Lo + E were significantly different among the three diplotype groups until 6 h after losartan administration (P < 0.01). On the contrary, AUC at the periods of 8–10 h and 10 h-infinity of Lo + E were significantly lower in the TT/TT group than in the GG/CC group. Urinary excretion of losartan until 4 h after losartan administration in the TT/TT group was higher than that of the GG/CC group. These results suggest that c.2677G>T/c.3435C>T diplotypes of ABCB1 may significantly increase the early-phase absorption of losartan, but not the total absorption.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA (2015) Losartan: Comprehensive Profile. Profiles Drug Subst Excip Relat Methodol 40:159–194. https://doi.org/10.1016/bs.podrm.2015.02.003
Aungst BJ (1993) Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci 82:979–987. https://doi.org/10.1002/jps.2600821008
Benet LZ, Wu CY, Herert MF, Wacher VJ (1996) Intestinal drug metabolism and antitransport process: a potential paradigm shift in oral drug delivery. J Control Release 39:139–143. https://doi.org/10.1016/0168-3659(95)00147-6
Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Jang CG, Lee SY, Lee YJ (2018a) The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem. Arch Pharm Res 41:931–936. https://doi.org/10.1007/s12272-018-1070-y
Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Jang CG, Lee SY, Lee YJ (2018b) Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem. Arch Pharm Res 41:861–866. https://doi.org/10.1007/s12272-018-1065-8
Byeon JY, Kim YH, Lee CM, Kim SH, Chae WK, Jung EH, Choi CI, Jang CG, Lee SY, Bae JW, Lee YJ (2018) CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes. Arch Pharm Res 41:921–930. https://doi.org/10.1007/s12272-018-1075-6
Byeon JY, Lee CM, Lee YJ, Kim YH, Kim SH, Jung EH, Chae WK, Lee YJ, Jang CG (2019) Lee SY (2019) Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine. Arch Pharm Res 42:182–190. https://doi.org/10.1007/s12272-018-1099-y
Byeon JY, Lee YJ, Kim YH, Kim SH, Lee CM, Bae JW, Jang CG, Lee SY, Choi CI (2018) Effects of diltiazem, a moderate inhibitor of CYP3A4, on the pharmacokinetics of tamsulosin in different CYP2D6 genotypes. Arch Pharm Res 41:564–570. https://doi.org/10.1007/s12272-018-1030-6
Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–174. https://doi.org/10.1067/mcp.2001.114164
Choi CI, Bae JW, Keum SK, Lee YJ, Lee HI, Jang CG, Lee SY (2013) Effects of OCT2 c.602C > T genetic variant on the pharmacokinetics of lamivudine. Xenobiotica 43:636–40. https://doi.org/10.3109/00498254.2012.747710
Choi CI, Lee YJ, Lee HI, Kim BH, Kim MJ, Jang CG, Bae JW, Lee SY (2012) Effects of the SLCO1B1*15 allele on the pharmacokinetics of pitavastatin. Xenobiotica 42:496–501. https://doi.org/10.3109/00498254.2011.632030
den Hartog AW, Franken R, van den Berg MP, Zwinderman AH, Timmermans J, Scholte AJ, de Waard V, Spijkerboer AM, Pals G, Mulder BJ, Groenink M (2016) The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutations. Neth Heart J 24:675–681. https://doi.org/10.1007/s12471-016-0905-8
Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, Swiss HIV Cohort Study (2002) Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30–36. https://doi.org/10.1016/S0140-6736(02)07276-8
Fung KL, Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 1794:860–871. https://doi.org/10.1016/j.bbapap.2009.02.014
Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E, Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM (2002) Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson’s disease. Pharmacogenetics 12:529–534. https://doi.org/10.1097/00008571-200210000-00004
Göktaş MT, Pepedil F, Karaca Ö, Kalkışım S, Cevik L, Gumus E, Guven GS, Babaoglu MO, Bozkurt A, Yasar U (2016) Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients. Eur Rev Med Pharmacol Sci 20:2460–2467
Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, Tanaka K, Inui K (2004) CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14:471–478. https://doi.org/10.1097/01.fpc.0000114747.08559.49
Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, Inui K (2002) C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than P-gp in recipients of living-donor liver transplantation. Pharmacogenetics 12:451–457. https://doi.org/10.1097/00008571-200208000-00005
Higgins CF (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8:67–113. https://doi.org/10.1146/annurev.cb.08.110192.000435
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene. Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–3478. https://doi.org/10.1073/pnas.050585397
Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA (2018) CYP3A5*3 and ABCB1 61A>G significantly influence dose-adjusted trough blood tacrolimus concentrations in the first three months post-kidney transplantation. Basic Clin Pharmacol Toxicol 123:320–326. https://doi.org/10.1111/bcpt.13016
Kazierad DJ, Martin DE, Blum RA, Tenero DM, Ilson B, Boike SC, Etheredge R, Jorkasky DK (1997) Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 62:417–425. https://doi.org/10.1016/S0009-9236(97)90120-X
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315:525–528. https://doi.org/10.1126/science.1135308
Kim MJ, Byeon JY, Kim YH, Kim SH, Lee CM, Jung EH, Chae WK, Lee YJ, Jang CG, Lee SY, Choi CI (2018) Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites. Arch Pharm Res 41:347–353. https://doi.org/10.1007/s12272-018-1005-7
Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199. https://doi.org/10.1067/mcp.2001.117412
Konstam MA, Neaton JD, Poole-Wilson PA, Pitt B, Segal R, Sharma D, Dasbach EJ, Carides GW, Dickstein K, Riegger G, Camm AJ, Martinez FA, Bradstreet DC, Ikeda LS, Santoro EP, Investigators ELITEII (2005) Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J 150:123–131. https://doi.org/10.1016/j.ahj.2004.10.035
Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Higuchi S, Otsubo K (2002) Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 72:209–219. https://doi.org/10.1067/mcp.2002.126177
Lee SW, Oh J, Kim AH, Ji SC, Park SI, Yoon SH, Chung JY, Yu KS, Jang IJ, Lee S (2020) Oral absorption of voriconazole is affected by SLCO2B1 c.*396T>C genetic polymorphism in CYP2C19 poor metabolizers. Pharmacogenomics J 20:792–800. https://doi.org/10.1038/s41397-020-0166-1
Li J, Wang X, Ning C, Wang Z, Wang Y, Zheng M, Zhang S, Lu Y, Zhang Y, Li N, Chen X, Zhao D (2020) Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects. Eur J Clin Pharmacol 76:1125–1133. https://doi.org/10.1007/s00228-020-02879-z
Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58:641–649. https://doi.org/10.1016/0009-9236(95)90020-9
Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M, Kasuga M, Okumura K (2002) Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 25:1356–1359. https://doi.org/10.1248/bpb.25.1356
Mulla S, Siddiqui WJ (2020) Losartan. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing
Naja K, El Shamieh S, Fakhoury R (2020) rs622342A>C in SLC22A1 is associated with metformin pharmacokinetics and glycemic response. Drug Metab Pharmacokinet 35:160–164. https://doi.org/10.1016/j.dmpk.2019.10.007
Oselin K, Nowakowski-Gashaw I, Mrozikiewicz PM, Wolberg D, Pahkla R (2003) Roots I (2003) Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. Eur J Clin Invest 33:261–267. https://doi.org/10.1046/j.1365-2362.2003.01133.x
Owen A, Goldring C, Morgan P, Chadwick D, Park BK, Pirmohamed M (2005) Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol 59:365–370. https://doi.org/10.1111/j.1365-2125.2005.02229.x
Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:747–752. https://doi.org/10.1016/s0140-6736(97)01187-2
Rigalli JP, Ciriaci N, Mottino AD, Catania VA, Ruiz ML (2016) Modulation of expression and activity of ABC transporters by the phytoestrogen genistein. Impact on drug disposition. Curr Med Chem 23:1370–1389. https://doi.org/10.2174/0929867323666160406120711
Ritter MA, Furtek CI, Lo MW (1997) An improved method for the simultaneous determination of losartan and its major metabolite, EXP3174, in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 15:1021–1029. https://doi.org/10.1016/s0731-7085(96)01948-6
Ruggenenti P (2017) Dual renin-angiotensin system blockade for nephroprotection. Nephrol Ther Suppl 1:S43–S45. https://doi.org/10.1016/j.nephro.2017.02.006
Sachinidis A, Ko Y, Weisser P, Meyer zu Brickwedde MK, Düsing R, Christian R, Wieczorek AJ, Vetter H (1993) EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells. J Hypertens 11:155–162. https://doi.org/10.1097/00004872-199302000-00007
Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Jiang-Zheng C, Koller D, Mejía G, Zubiaur P, Wojnicz A, Abad-Santos F (2018) Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants. Basic Clin Pharmacol Toxicol 123:474–485. https://doi.org/10.1111/bcpt.13031
Sakaeda T (2005) MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 20:391–414. https://doi.org/10.2133/dmpk.20.391
Schwab M, Eichelbaum M, Fromm MF (2003) Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285–307. https://doi.org/10.1146/annurev.pharmtox.43.100901.140233
Siegmund W, Ludwig K, Giessmann T, Dazert P, Schroeder E, Sperker B, Warzok R, Kroemer HK, Cascorbi I (2002) The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72:572–583. https://doi.org/10.1067/mcp.2002.127739
Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira RJ, Carvalho F, de Lourdes BM, Remião F (2015) Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther 149:1–123. https://doi.org/10.1016/j.pharmthera.2014.11.013
Soldner A, Benet LZ, Mutschler E, Christians U (2000) Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol 129:1235–1243. https://doi.org/10.1038/sj.bjp.0703150
Stearns RA, Chakravarty PK, Chen R, Chiu SH (1995) Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochromeP4502C and 3A subfamily members. Drug Metab Dispos 23:207–215
Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143
Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735–7738. https://doi.org/10.1073/pnas.84.21.7735
Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129–134. https://doi.org/10.1002/mc.2940130302
Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT (2015) Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet 54:709–735. https://doi.org/10.1007/s40262-015-0267-1
Yasar U, Babaoglu MO, Bozkurt A (2008) Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1). Basic Clin Pharmacol Toxicol 103:176–179. https://doi.org/10.1111/j.1742-7843.2008.00283.x
Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F, Eliasson E, Dahl ML (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71:89–98. https://doi.org/10.1067/mcp.2002.121216
Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, Eliasson E (2001) Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 29:1051–1056
Zhou SF (2008) Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38:802–832. https://doi.org/10.1080/00498250701867889
Acknowledgements
This research was supported the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, & Future Planning (NRF-2019R1A2C1004582).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shin, HB., Jung, E.H., Kang, P. et al. ABCB1 c.2677G>T/c.3435C>T diplotype increases the early-phase oral absorption of losartan. Arch. Pharm. Res. 43, 1187–1196 (2020). https://doi.org/10.1007/s12272-020-01294-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-020-01294-3